Batimastat ophthalmic - InSite Vision

Drug Profile

Batimastat ophthalmic - InSite Vision

Alternative Names: Batimastat - InSite Vision; ISV 120; ISV 615

Latest Information Update: 30 May 2007

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator British Biotech
  • Developer InSite Vision
  • Class Aromatic amino acids; Essential amino acids; Small molecules; Thiophenes
  • Mechanism of Action Collagenase inhibitors; Metalloprotease inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Diabetic retinopathy; Macular degeneration; Recurrent pterygium

Most Recent Events

  • 19 Apr 2001 Discontinued-II for Recurrent pterygium in USA (Ophthalmic)
  • 09 Aug 1999 Phase-I clinical trials for Macular degeneration in USA (Ophthalmic)
  • 09 Aug 1999 Preclinical development for Diabetic retinopathy in USA (Ophthalmic)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top